Med Life (BSE:M) Piotroski F-Score: 6 (As of Jun. 26, 2026) — Near Median


BSE:M Med Life SA BSE:M
91 GF Score
Price lei11.40
GF Value lei7.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Med Life Piotroski F-Score?

Med Life BSE:M +0.71% 91 Piotroski F-Score is 6 as of Jun. 26, 2026, which is at its 10-year median of 6.00. GuruFocus rates BSE:M with a GF Score™ of 91/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 652 Healthcare Providers & Services companies, Med Life ranks better than 74.69% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Med Life has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Med Life's Piotroski F-Score or its related term are showing as below:

BSE:M' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 6

During the past 11 years, the highest Piotroski F-Score of Med Life was 9. The lowest was 2. And the median was 6.

Med Life  (BSE:M) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Med Life Piotroski F-Score Related Terms


Med Life Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Med Life's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med Life Piotroski F-Score Chart

Med Life Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 9.00 5.00 4.00 6.00

Med Life Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 6.00 6.00

BSE:M vs HCA, THC, DVA: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, Med Life's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Med Life Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Med Life's Piotroski F-Score falls into.


BSE:M
91GF Score
Med Life SA BSE:M
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Dec24) TTM:
Net Income was 13.377 + -15.938 + 7.244 + 9.783 = lei14 Mil.
Cash Flow from Operations was 90.889 + 9.687 + 73.522 + 70.662 = lei245 Mil.
Revenue was 777.633 + 796.324 + 787.959 + 853.14 = lei3,215 Mil.
Gross Profit was 632.138 + 636.249 + 628.257 + 681.599 = lei2,578 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Mar26) was
(3022.348 + 3081.942 + 3104.257 + 3142.851 + 3335.797) / 5 = lei3137.439 Mil.
Total Assets at the begining of this year (Dec24) was lei3,022 Mil.
Long-Term Debt & Capital Lease Obligation was lei1,782 Mil.
Total Current Assets was lei743 Mil.
Total Current Liabilities was lei930 Mil.
Net Income was 14.462 + 5.945 + 4.743 + 0.396 = lei26 Mil.

Revenue was 646.622 + 663.778 + 668.269 + 736.788 = lei2,715 Mil.
Gross Profit was 534.302 + 541.974 + 544.012 + 595.953 = lei2,216 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(2636.337 + 2747.092 + 2771.102 + 2949.993 + 3022.348) / 5 = lei2825.3744 Mil.
Total Assets at the begining of last year (Dec23) was lei2,636 Mil.
Long-Term Debt & Capital Lease Obligation was lei1,488 Mil.
Total Current Assets was lei656 Mil.
Total Current Liabilities was lei977 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Med Life's current Net Income (TTM) was 14. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Med Life's current Cash Flow from Operations (TTM) was 245. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=14.466/3022.348
=0.00478634

ROA (Last Year)=Net Income/Total Assets (Dec23)
=25.546/2636.337
=0.00968996

Med Life's return on assets of this year was 0.00478634. Med Life's return on assets of last year was 0.00968996. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Med Life's current Net Income (TTM) was 14. Med Life's current Cash Flow from Operations (TTM) was 245. ==> 245 > 14 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Mar26
=1781.626/3137.439
=0.56785996

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1488.195/2825.3744
=0.52672488

Med Life's gearing of this year was 0.56785996. Med Life's gearing of last year was 0.52672488. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=742.575/929.699
=0.79872625

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=655.868/977.49
=0.67097157

Med Life's current ratio of this year was 0.79872625. Med Life's current ratio of last year was 0.67097157. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Med Life's number of shares in issue this year was 530.816. Med Life's number of shares in issue last year was 531.065. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2578.243/3215.056
=0.80192787

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2216.241/2715.457
=0.81615765

Med Life's gross margin of this year was 0.80192787. Med Life's gross margin of last year was 0.81615765. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=3215.056/3022.348
=1.06376102

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=2715.457/2636.337
=1.03001134

Med Life's asset turnover of this year was 1.06376102. Med Life's asset turnover of last year was 1.03001134. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Med Life has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Med Life (BSE:M) has a Piotroski F-Score of 6 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Med Life and its competitors. This is near median its historical median of 6.00. Over the past decade, Med Life's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Med Life ranks #165 out of 652 companies in the Healthcare Providers & Services industry, placing it in the top 25.3%.
Is Med Life's Piotroski F-Score too high?
Med Life's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Med Life's value of 6 is 20% above this industry median. Based on the distribution chart, Med Life ranks #165 out of 652 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Med Life has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #165 out of 652 companies for Piotroski F-Score. This puts Med Life in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Med Life's value of 6 is 20% above this benchmark. Historically, Med Life's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.40 — trading 45.8% above its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Healthcare Providers & Services industry median of 5.00. Med Life's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Med Life (BSE:M), the current Piotroski F-Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Med Life (BSE:M) Overvalued in 2026?

Based on GuruFocus' analysis, Med Life stock appears to be overvalued. The current stock price of lei11.40 is trading 45.8% above its estimated GF Value™ of lei7.82. GuruFocus considers Med Life to be Significantly Overvalued.

Key valuation signals for BSE:M:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: lei7.82 vs. price of lei11.40 (45.8% above fair value)
  • GF Score™: 91/100 with 4 warning signs
  • Industry Position: 20% above the Healthcare Providers & Services median (#165 of 652)

No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Med Life Business Description

Other Exchanges 0RO5:UKO0C:Germany
Address Calea Grivitei, No. 365, District 1, Bucharest, ROU
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
91GF Score

Get the complete analysis for BSE:M

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei11.40
Price
lei7.82
GF Value